Titan Bio-Tech [TITANBIO] vs OneSource Specialty [ONESOURCE] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Titan Bio-Tech Ltd. wins in 11 metrics, OneSource Specialty Pharma Inc. wins in 5 metrics, with 0 ties. Titan Bio-Tech Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Titan Bio-Tech Ltd. | OneSource Specialty Pharma Inc. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 74.64 | 936.63 | Titan Bio-Tech Ltd. |
| Price-to-Book Ratio | 12.19 | 3.11 | OneSource Specialty Pharma Inc. |
| Debt-to-Equity Ratio | 5.32 | 21.93 | Titan Bio-Tech Ltd. |
| PEG Ratio | -1.22 | 42.24 | OneSource Specialty Pharma Inc. |
| EV/EBITDA | 61.34 | 40.79 | OneSource Specialty Pharma Inc. |
| Profit Margin (TTM) | 14.13% | 1.42% | Titan Bio-Tech Ltd. |
| Operating Margin (TTM) | 16.92% | -18.02% | Titan Bio-Tech Ltd. |
| EBITDA Margin (TTM) | 16.92% | N/A | N/A |
| Return on Equity | 14.04% | -0.31% | Titan Bio-Tech Ltd. |
| Return on Assets (TTM) | 12.32% | -0.24% | Titan Bio-Tech Ltd. |
| Free Cash Flow (TTM) | $106.79M | $-1.96B | Titan Bio-Tech Ltd. |
| Dividend Yield | 0.42% | N/A | N/A |
| 1-Year Return | 419.45% | -20.38% | Titan Bio-Tech Ltd. |
| Price-to-Sales Ratio (TTM) | 10.54 | 13.01 | Titan Bio-Tech Ltd. |
| Enterprise Value | $20.35B | $195.90B | OneSource Specialty Pharma Inc. |
| EV/Revenue Ratio | 10.57 | 13.80 | Titan Bio-Tech Ltd. |
| Gross Profit Margin (TTM) | N/A | 67.50% | N/A |
| Revenue per Share (TTM) | $47 | $124 | OneSource Specialty Pharma Inc. |
| Earnings per Share (Diluted) | $6.58 | $1.72 | Titan Bio-Tech Ltd. |
| Beta (Stock Volatility) | -0.48 | N/A | N/A |
Titan Bio-Tech Ltd. vs OneSource Specialty Pharma Inc. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Titan Bio-Tech Ltd. | 0.80% | 3.09% | -1.02% | 28.03% | 96.24% | 110.92% |
| OneSource Specialty Pharma Inc. | 0.68% | -6.58% | -11.52% | 8.72% | 0.44% | -9.19% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Titan Bio-Tech Ltd. | 419.45% | 756.94% | 499.88% | 6,742.31% | 9,962.22% | 20,395.39% |
| OneSource Specialty Pharma Inc. | -20.38% | -5.70% | -5.70% | -5.70% | -5.70% | -5.70% |
Performance & Financial Health Analysis: Titan Bio-Tech Ltd. vs OneSource Specialty Pharma Inc.
| Metric | TITANBIO | ONESOURCE |
|---|---|---|
| Market Information | ||
| Market Cap | ₹19.90B | ₹202.76B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 68,890 | 1,038,625 |
| 90 Day Avg. Volume | 156,601 | 610,058 |
| Last Close | ₹448.30 | ₹1,623.40 |
| 52 Week Range | ₹74.73 - ₹555.65 | ₹1,057.00 - ₹2,248.00 |
| % from 52W High | -19.32% | -27.78% |
| All-Time High | ₹1,460.00 (Feb 18, 2026) | ₹2,248.00 (Jun 18, 2025) |
| % from All-Time High | -69.29% | -27.78% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.48% | -0.26% |
| Quarterly Earnings Growth | 0.94% | N/A |
| Financial Health | ||
| Profit Margin (TTM) | 0.14% | 0.01% |
| Operating Margin (TTM) | 0.17% | -0.18% |
| Return on Equity (TTM) | 0.14% | 0.00% |
| Debt to Equity (MRQ) | 5.32 | 21.93 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹40.29 | ₹518.08 |
| Cash per Share (MRQ) | ₹0.87 | ₹14.56 |
| Operating Cash Flow (TTM) | ₹197.75M | ₹-2,152,760,000 |
| Levered Free Cash Flow (TTM) | ₹215.32M | ₹-179,710,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.42% | N/A |
| Last 12-Month Dividend | ₹4.00 | N/A |
Valuation & Enterprise Metrics Analysis: Titan Bio-Tech Ltd. vs OneSource Specialty Pharma Inc.
| Metric | TITANBIO (Apr 24, 2026) | ONESOURCE (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 74.64 | 936.63 |
| Forward P/E | N/A | 42.24 |
| PEG Ratio | -1.22 | 42.24 |
| Price to Sales (TTM) | 10.54 | 13.01 |
| Price to Book (MRQ) | 12.19 | 3.11 |
| Market Capitalization | ||
| Market Capitalization | ₹19.90B | ₹202.76B |
| Enterprise Value | ₹20.35B | ₹195.90B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 10.57 | 13.80 |
| Enterprise to EBITDA | 61.34 | 40.79 |
| Risk & Other Metrics | ||
| Beta | -0.48 | N/A |
| Book Value per Share (MRQ) | ₹40.29 | ₹518.08 |
Financial Statements Comparison: Titan Bio-Tech Ltd. vs OneSource Specialty Pharma Inc.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | TITANBIO (2025) | ONESOURCE (2025) |
|---|---|---|
| Revenue/Sales | 1.56B | 14.45B |
| Cost of Goods Sold | 892.53M | 4.35B |
| COGS % of Revenue | 57.0% | 30.1% |
| Gross Profit | 671.98M | 10.10B |
| Gross Margin | 43.0% | 69.9% |
| Research & Development | N/A | 20.49M |
| Operating Income (EBIT) | 212.57M | 1.90B |
| Operating Margin | 13.6% | 13.2% |
| EBITDA | 285.61M | 4.71B |
| EBITDA Margin | 18.3% | 32.6% |
| Pre-Tax Income | 243.67M | -670.66M |
| Pre-Tax Income % of Revenue | 15.6% | -4.6% |
| Income Tax | 60.96M | -497.85M |
| Income Tax % of Revenue | 3.9% | -3.4% |
| Net Income (Profit) | 215.32M | -179.71M |
| Profit Margin | 13.8% | -1.2% |
Balance Sheet & Liquidity Metrics
| Metric | TITANBIO (2025) | ONESOURCE (2025) |
|---|---|---|
| Cash & Equivalents | 51.28M | 1.56B |
| Total Current Assets | 790.38M | 10.86B |
| Total Current Assets % of Revenue | 50.5% | 75.2% |
| Total Current Liabilities | 177.36M | 11.14B |
| Total Current Liabilities % of Revenue | 11.3% | 77.1% |
| Long-Term Debt | 4.19M | 3.83B |
| Long-Term Debt % of Revenue | 0.3% | 26.5% |
| Total Shareholders Equity | 1.53B | 58.81B |
| Retained Earnings | 1.36B | -18.43B |
| Retained Earnings % of Revenue | 87.0% | -127.6% |
| Property, Plant & Equipment | 571.62M | 8.97B |
Cash Flow Statement Comparison
| Metric | TITANBIO (2025) | ONESOURCE (2025) |
|---|---|---|
| Operating Cash Flow | 197.75M | -2.15B |
| Operating Cash Flow % of Revenue | 12.6% | -14.9% |
| Capital Expenditures | -85.26M | N/A |
| Free Cash Flow | 106.79M | -1.96B |
| FCF Margin | 6.8% | -13.6% |
| Debt Repayment | -2.69M | -6.31B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | TITANBIO | ONESOURCE |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 41.32M | 114.64M |
| Float Shares | 13.13M | 70.43M |
| % Held by Insiders | 68.21% | 38.63% |
| % Held by Institutions | 0.00% | 26.67% |
| % Held by Public | 31.79% | 34.70% |
Dividend Analysis & Yield Comparison: Titan Bio-Tech Ltd. vs OneSource Specialty Pharma Inc.
| Metric | TITANBIO | ONESOURCE |
|---|---|---|
| Last 12-Month Dividend | ₹4.00 | N/A |
| Last 12-Month Dividend Yield | 0.42% | N/A |
| 3-Year Avg Annual Dividend | ₹1.93 | N/A |
| 3-Year Avg Dividend Yield | 0.34% | N/A |
| 3-Year Total Dividends | ₹5.80 | N/A |
| Ex-Dividend Date | Sep 19, 2025 | N/A |